Scandion Oncology As Stock Current Valuation
| SCOL Stock | SEK 0.06 0 4.62% |
Valuation analysis of Scandion Oncology helps investors to measure Scandion Oncology's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Scandion Oncology's price fluctuation is out of control at this time. Calculation of the real value of Scandion Oncology is based on 3 months time horizon. Increasing Scandion Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Scandion Oncology's intrinsic value may or may not be the same as its current market price of 0.06, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.062 | Real 0.0595 | Hype 0.06 | Naive 0.0718 |
The intrinsic value of Scandion Oncology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Scandion Oncology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Scandion Oncology AS helps investors to forecast how Scandion stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Scandion Oncology more accurately as focusing exclusively on Scandion Oncology's fundamentals will not take into account other important factors: Scandion Oncology AS Company Current Valuation Analysis
Scandion Oncology's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Scandion Oncology Current Valuation | (6.85 M) |
Most of Scandion Oncology's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Scandion Oncology AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Scandion Oncology AS has a Current Valuation of (6.85 Million). This is 100.05% lower than that of the Healthcare sector and 100.15% lower than that of the Biotechnology industry. The current valuation for all Sweden stocks is 100.04% higher than that of the company.
Scandion Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Scandion Oncology's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Scandion Oncology could also be used in its relative valuation, which is a method of valuing Scandion Oncology by comparing valuation metrics of similar companies.Scandion Oncology is currently under evaluation in current valuation category among its peers.
Scandion Fundamentals
| Return On Equity | -0.74 | |||
| Return On Asset | -0.42 | |||
| Operating Margin | 473.28 % | |||
| Current Valuation | (6.85 M) | |||
| Shares Outstanding | 40.71 M | |||
| Shares Owned By Insiders | 1.82 % | |||
| Price To Book | 1.01 X | |||
| Price To Sales | 969.63 X | |||
| Gross Profit | (32.32 M) | |||
| EBITDA | (55.84 M) | |||
| Net Income | (51.7 M) | |||
| Cash And Equivalents | 131.54 M | |||
| Cash Per Share | 4.09 X | |||
| Current Ratio | 13.92 X | |||
| Book Value Per Share | 2.10 X | |||
| Cash Flow From Operations | (49.8 M) | |||
| Earnings Per Share | (1.74) X | |||
| Target Price | 3.87 | |||
| Number Of Employees | 14 | |||
| Beta | 0.48 | |||
| Market Capitalization | 111.79 M | |||
| Total Asset | 116.22 M | |||
| Net Asset | 116.22 M |
About Scandion Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Scandion Oncology AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Scandion Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Scandion Oncology AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Scandion Stock Analysis
When running Scandion Oncology's price analysis, check to measure Scandion Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scandion Oncology is operating at the current time. Most of Scandion Oncology's value examination focuses on studying past and present price action to predict the probability of Scandion Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scandion Oncology's price. Additionally, you may evaluate how the addition of Scandion Oncology to your portfolios can decrease your overall portfolio volatility.